News

Phase 2 Trial Testing Seliciclib for Cushing’s Disease Is Recruiting Participants

A new Phase 2 trial evaluating the promising investigative therapy seliciclib as a treatment for Cushing’s disease is currently enrolling participants. The trial (NCT02160730), at Cedars-Sinai Medical Center in Los Angeles, will evaluate whether seliciclib can safely suppress the production of adrenocorticotropic hormone (ACHT) secreted by the pituitary tumors, normalizing…

NIH Agency Pioneers Collaborative Research into Rare Diseases

A little-known government entity within the National Institutes of Health (NIH) is helping to lead U.S. efforts to speed up the development of therapies for some 7,000 rare diseases. The Office of Rare Diseases Research (ORDR), headquartered in Bethesda, Maryland, was established in 1993 within the NIH Office of the…